{
  "nctId": "NCT00782756",
  "briefTitle": "Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma",
  "officialTitle": "A Phase II Study of Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma",
  "protocolDocument": {
    "nctId": "NCT00782756",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2009-04-28",
    "uploadDate": "2017-12-13T14:56",
    "size": 1038202,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT00782756/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 40,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2008-10-28",
    "completionDate": "2017-03-23",
    "primaryCompletionDate": "2017-03-23",
    "firstSubmitDate": "2008-10-29",
    "firstPostDate": "2008-10-31"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Pathologic diagnosis of glioblastoma or grade IV glioma.\n* Tumor volume should be less than 60 cc (approximately 5cm maximum diameter).\n* Age \\> or = to 18\n* KPS ≥70\n* Granulocyte count \\>1.5 X 10 9/L\n* Platelet count \\>99 X 10 9/L\n* SGOT \\< 2.5X upper limit of normal (ULN)\n* Serum creatinine \\< 2X ULN\n* Bilirubin \\< 2X ULN\n* All patients must sign written informed consent\n\nExclusion Criteria:\n\n* Any prior chemotherapy, radiotherapy and biologic therapy for glioma.\n* Any prior experimental therapy for glioma.\n* Multicentric glioma\n* Other concurrent active malignancy (with the exception of cervical carcinoma in situ or basal cell ca of the skin).\n* Serious medical or psychiatric illness that would in the opinion of the investigator interfere with the prescribed treatment.\n* Pregnant or breast feeding women.\n* Refusal to use effective contraception\n* Inadequately controlled hypertension (defined as systolic blood pressure \\>150 mmHg and/or diastolic blood pressure \\> 100 mmHg)\n* Prior history of hypertensive crisis or hypertensive encephalopathy\n* New York Heart Association (NYHA) Grade II or greater congestive heart failure\n* History of myocardial infarction or unstable angina within 12 months prior to Day 1\n* History of stroke or transient ischemic attack\n* Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1\n* History of hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1\n* Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of treatment or anticipation of need for major surgical procedure during the course of the study\n* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1\n* History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1\n* Serious, non-healing wound, active ulcer, or untreated bone fracture\n* Proteinuria as demonstrated by a UPC ratio ≥ 1.0 at screening\n* Known hypersensitivity to any component of bevacizumab",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number of Participants With Adverse Events",
        "description": "Safety assessments and toxicity grading will follow CTCAE Version 4 Grade",
        "timeFrame": "through study completion, an average of 1 year"
      }
    ],
    "secondary": [
      {
        "measure": "Progression Free Survival",
        "timeFrame": "through study completion, an average of 1 year"
      },
      {
        "measure": "Neurocognitive Outcome",
        "timeFrame": "through study completion, an average of 1 year"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 2,
      "otherCount": 0,
      "totalCount": 3
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 24,
    "complexityCategory": "Simple"
  },
  "collectionDate": "2025-09-22T02:30:56.248Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}